HSBC Upgrades Novartis to Hold, Raises Price Target to $136

Benzinga Newsdesk www.benzinga.com Positive 84.3%

Neg 0% Neu 0% Pos 84.3%

HSBC analyst Rajesh Kumar upgrades Novartis (NYSE:NVS) from Reduce to Hold and raises the price target from $123 to $136.